Innate Pharma SA
PAR:IPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
PAR:IPH
|
FR |
|
SECURE Waste Infrastructure Corp
F:SEP0
|
CA |
|
F
|
Fitell Corp
NASDAQ:FTEL
|
AU |
|
S
|
Satellos Bioscience Inc
XTSX:MSCL
|
CA |
|
L
|
La Doria SpA
F:2DO
|
IT |
|
Mega Uranium Ltd
F:M6J
|
CA |
|
CP All PCL
OTC:CPPCY
|
TH |
|
Pharnext SA
PAR:ALPHA
|
FR |
|
P
|
Profile Systems and Software SA
ATHEX:PROF
|
GR |
|
C
|
CP All PCL
SET:CPALL
|
TH |
|
J
|
JDC Corp
F:JDD
|
JP |
|
Cardinal Energy Ltd (Alberta)
F:C0Y
|
CA |
|
Fix Price Group Ltd
LSE:FIXP
|
RU |
|
F
|
FiscalNote Intermediate Holdco Inc
NYSE:NOTE
|
US |
Wall St Price Targets
IPH Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IPH is 5.457 EUR with a low forecast of 4.545 EUR and a high forecast of 6.51 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IPH's stock price target?
Price Target
5.457
EUR
According to Wall Street analysts, the average 1-year price target for IPH is 5.457 EUR with a low forecast of 4.545 EUR and a high forecast of 6.51 EUR.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
